sana biotechnology is focused on utilizing engineered cells as medicines for patients. the ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. sana is building differentiated capabilities across the spectrum of cell and gene therapy. three aspirations drive sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. the first is the ability to repair and control the genes in any cell in the body. we are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. last is a belief we can enable broader access to ou
![Sana Biotechnology logo](https://files.capedge.com/10-K/0001193125-21-092650/g124805g55l64.jpg)
Company profile
Ticker
SANA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cobalt Biomedicine, Inc. • Oscine Corp. • Cytocardia, Inc. ...
SANA stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
S-8
Registration of securities for employees
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
S-3ASR
Automatic shelf registration
1 Mar 24
8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29 Feb 24
Latest ownership filings
4/A
Patrick Y Yang
15 Jul 24
4/A
Richard Mulligan
15 Jul 24
4/A
ROBERT NELSEN
15 Jul 24
4/A
Mary Agnes Wilderotter
15 Jul 24
4/A
Michelle Seitz
15 Jul 24
4/A
ALISE REICIN
15 Jul 24
4/A
Douglas G. Cole
15 Jul 24
4/A
Hans Edgar Bishop
15 Jul 24
4/A
Joshua H. Bilenker
15 Jul 24
4
Hans Edgar Bishop
8 Jul 24
Financial summary
Quarter (USD) | Mar 24 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.89 mm | 180.89 mm | 180.89 mm | 180.89 mm | 180.89 mm | 180.89 mm |
Cash burn (monthly) | (no burn) | 532.25 k | 36.91 mm | 26.10 mm | 21.88 mm | 22.27 mm |
Cash used (since last report) | n/a | 2.06 mm | 142.70 mm | 100.93 mm | 84.59 mm | 86.11 mm |
Cash remaining | n/a | 178.83 mm | 38.19 mm | 79.96 mm | 96.30 mm | 94.78 mm |
Runway (months of cash) | n/a | 336.0 | 1.0 | 3.1 | 4.4 | 4.3 |
Institutional ownership, Q1 2024
95.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 149 |
Opened positions | 71 |
Closed positions | 10 |
Increased positions | 30 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 1.35 tn |
Total shares | 210.37 mm |
Total puts | 123.60 k |
Total calls | 297.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund IX | 44.04 mm | $0.00 |
Flagship Pioneering | 25.00 mm | $250.02 bn |
FMR | 22.04 mm | $220.43 bn |
Flagship Ventures Fund V | 21.17 mm | $0.00 |
Vanguard | 12.16 mm | $121.55 bn |
Baillie Gifford & Co | 10.66 mm | $106.56 bn |
Canada Pension Plan Investment Board | 10.18 mm | $101.75 bn |
BLK Blackrock | 9.05 mm | $90.46 bn |
STT State Street | 6.37 mm | $63.70 bn |
Capital World Investors | 5.45 mm | $54.49 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jul 24 | Bishop Hans Edgar | Common Stock | Grant | Acquire A | No | No | 0 | 4,911 | 0.00 | 5,784,551 |
6 Jun 24 | Reicin Alise | Stock Option Common Stock | Grant | Acquire A | No | No | 7.36 | 54,278 | 399.49 k | 54,278 |
6 Jun 24 | Mulligan Richard | Stock Option Common Stock | Grant | Acquire A | No | No | 7.36 | 54,278 | 399.49 k | 54,278 |
6 Jun 24 | Wilderotter Mary Agnes | Stock Option Common Stock | Grant | Acquire A | No | No | 7.36 | 54,278 | 399.49 k | 54,278 |
6 Jun 24 | Nelsen Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 7.36 | 54,278 | 399.49 k | 54,278 |
News
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Jul 24
Sana Biotechnology Showcases Nature Biotechnology Publication Of In Vivo Preclinical Data Demonstrating Potential Of Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation For Treating Huntington's Disease And Other Glial-Based Neurodegenerative Conditions
21 May 24
HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target
9 May 24
Sana Biotechnology Q1 Adj $(0.32), Inline
8 May 24
Press releases
Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World
25 Jul 24
Alltrna Announces Updates to Its Board of Directors
17 Jul 24
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability
10 Jul 24
Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions
10 Jul 24
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
12 Jun 24